Flash Finance

Dr. Agarwal's Health Care LimitedAGARWALEYECorporate

Healthcare Medical Instruments & Supplies Latest results: Jun 2026 11 quarters of data
Consolidated Standalone
₹465.80
MCap ₹14,767 Cr · P/E 79.8
Dr. Agarwal's Health Care Limited — Stock analysis & AI research Dr. Agarwal's Health Care Limited — Multibagger AI analysis Dr. Agarwal's Health Care Limited — Seasonality — best & worst months Dr. Agarwal's Health Care Limited — Technical indicators & charts Dr. Agarwal's Health Care Limited — Technical setup — score, trend, support & resistance Dr. Agarwal's Health Care Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Sales Growth Stocks📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹614 Cr
Sales · Jun 2026
+26.1% YoY
₹170 Cr
Operating Profit · Jun 2026
+20.9% YoY
27.8%
OPM % · Jun 2026
-4.1% YoY
₹55 Cr
Net Profit · Jun 2026
+44.8% YoY
₹1.43
EPS · Jun 2026
+50.5% YoY

📝 Dr. Agarwal's Health Care Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Dr. Agarwal's Health Care Limited reported revenue of ₹614 crore for the quarter ended June 2026 (Q1 FY27), up 26.1% from ₹487 crore in the same quarter last year, and up 8.9% sequentially over the March 2026 quarter.

Net profit rose 44.8% year-on-year to ₹55 crore, from ₹38 crore. Earnings per share (EPS) came in at ₹1.43.

Operating profit stood at ₹170 crore — an operating margin (OPM) of 27.8%, compared with 29.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dr. Agarwal's Health Care Limited posted revenue of ₹2,080 crore, a growth of 21.6% over FY25, with a net profit of ₹168 crore (up 52.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,207 crore with a net profit of ₹185 crore.

Valuation snapshot

At the current price of ₹465.80, AGARWALEYE has a market capitalisation of ₹14,767 crore and a trailing P/E of about 79.8.

Within the Medical Instruments & Supplies industry, it is the 3rd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 32.33%, foreign institutional investors (FIIs) 49.56%, domestic institutional investors (DIIs) 15.87%, public shareholders 2.24% of Dr. Agarwal's Health Care Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,767 Cr
Current Price ?
₹465.8
P/E ?
79.81below ind
Industry P/E ?
100.10
P/B ?
7.29
P/S ?
6.69
P/FCF ?
250.29
Enterprise Value ?
₹15,833 Cr
EV/EBITDA ?
25.44
PEG ?
6.14
Earnings Yield ?
2.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹2,207 Cr
OPM ?
28.2%
Profit after tax (TTM) ?
₹185 Cr
EPS (TTM) ?
₹5.84
ROCE ?
11.0%
ROE ?
9.1%
ROA ?
4.7%
Growth
Sales — latest qtr ?
₹614 Cr
PAT — latest qtr ?
₹55 Cr
YoY qtr sales growth ?
26.1%
YoY qtr profit growth ?
44.8%
Sales growth (3y) ?
27%
Sales growth (5y) ?
35%
Profit growth (3y) ?
13%
Profit growth (5y) ?
34%
Financial Health
Debt ?
₹1,066 Cr
Debt to Equity ?
0.53
Interest Coverage ?
3.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
32.33%
Change in promoter holding ?
-0.10%
Pledged percentage ?
N/A
Market
Return 3 months ?
-4.1%
Return 6 months ?
4.9%

🗓️ Quarterly results (11 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 333349403417431460487499530564614 +26.1% +8.9%
Operating Profit 89108104107115131141136155161170 +20.9% +5.8%
Other Income 1220612131314810146 -54.2% -54.2%
Interest 2227272828252523212223 -6.5% +6.2%
Depreciation 4347565758606368697778 +24.3% +1.7%
Profit Before Tax 3654273341595454657775 +39.1% -2.4%
Net Profit 2341182128433836445055 +44.8% +10.0%
EPS ————0.731.030.950.941.071.251.43 +50.5% +14.4%
OPM % 26.7% 30.9% 25.8% 25.7% 26.7% 28.5% 29.0% 27.3% 29.2% 28.5% 27.8% -4.1% -2.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,711 Cr ₹2,080 Cr ₹2,207 Cr +21.6%
Operating Profit ₹457 Cr ₹593 Cr ₹622 Cr +29.8%
OPM % 26.70% 28.51% 28.20% +6.8%
NPM % 6.44% 8.08% 8.38% +25.5%
Other Income ₹44 Cr ₹46 Cr ₹38 Cr +5.2%
Depreciation ₹231 Cr ₹277 Cr ₹292 Cr +19.8%
Interest ₹108 Cr ₹91 Cr ₹89 Cr -16.0%
EBIT ₹226 Cr ₹316 Cr ₹330 Cr +40.1%
PBT ₹160 Cr ₹250 Cr ₹271 Cr +56.3%
Tax ₹13 Cr — ₹20 Cr —
Net Profit ₹110 Cr ₹168 Cr ₹185 Cr +52.4%
EPS ₹1.76 ₹4.21 ₹4.69 +139.2%
Material Cost ₹106 Cr — ₹136 Cr —
Employee Cost ₹84 Cr — ₹121 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 893232 +0.0%
Reserves 6221,3301,8351,994 +8.7%
Borrowings 8579669611,066 +10.9%
Other Liabilities 336445837850 +1.6%
Total Liabilities 1,8232,7513,6653,942 +7.6%
Fixed Assets 1,2931,7462,5232,879 +14.1%
CWIP 99118153234 +52.9%
Investments 34471264152 -42.4%
Other Assets 397416724676 -6.6%
Total Assets 1,8232,7513,6653,942 +7.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 233346360519 +44.2%
Cash from Investing Activity -509-914-750-308 +58.9%
Cash from Financing Activity 303553382-220 -157.6%
Net Cash Flow 27-15-8-10 -25.0%
Free Cash Flow 761184059 +47.5%
CFO/OP 98%103%86%101% +17.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 27272628 +7.7%
Inventory Days 116138181178 -1.7%
Days Payable 326355345283 -18.0%
Cash Conversion Cycle -183-190-138-76 +44.9%
Working Capital Days -62-65-44-3 +93.2%
ROCE % 13%11%10%11% +10.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 32.43%32.43%32.39%32.35%32.34%32.33% -0.0%
FIIs 59.26%58.13%58.06%57.94%57.96%49.56% -14.5%
DIIs 6.44%7.92%7.78%7.83%7.72%15.87% +105.6%
Public 1.87%1.52%1.78%1.87%1.98%2.24% +13.1%
No. of Shareholders 63,02148,16846,55443,53842,49242,055 -1.0%

⚖️ Peer comparison

Industry: Medical Instruments & Supplies · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 LENSKART LENSKART SOLUTIONS ₹681.90 118,107 180.2 9,634 668 20.8% 6.9% — — 43.3% 274.5%
2 POLYMED Poly Medicure ₹1,720.90 17,443 55.4 2,024 313 22.8% 15.5% 13.9% -5.1% 30.3% -8.4%
3 AGARWALEYE DR AGARWALS ₹475.30 15,068 101.3 2,207 185 28.2% 8.4% 21.6% 52.4% 26.1% 44.8%
❓ Frequently asked questions
What was Dr. Agarwal's Health Care Limited's revenue in Q1 FY27?
Dr. Agarwal's Health Care Limited reported revenue of ₹614 crore for the quarter ended June 2026 (Q1 FY27), up 26.1% from ₹487 crore in the same quarter last year, and up 8.9% sequentially over the March 2026 quarter.
What was Dr. Agarwal's Health Care Limited's net profit in Q1 FY27?
Net profit rose 44.8% year-on-year to ₹55 crore, from ₹38 crore. Earnings per share (EPS) came in at ₹1.43.
What is AGARWALEYE's market capitalisation and P/E ratio?
At the current price of ₹465.80, AGARWALEYE has a market capitalisation of ₹14,767 crore and a trailing P/E of about 79.8.
Who owns Dr. Agarwal's Health Care Limited? (shareholding pattern)
As of Sep 2026, promoters held 32.33%, foreign institutional investors (FIIs) 49.56%, domestic institutional investors (DIIs) 15.87%, public shareholders 2.24% of Dr. Agarwal's Health Care Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI